Published in Nat Med on September 20, 2009
Immunity, inflammation, and cancer. Cell (2010) 28.27
Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol (2010) 8.87
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol (2011) 5.73
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity (2012) 5.08
Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature (2010) 4.10
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med (2011) 4.02
The interleukin-1 family: back to the future. Immunity (2013) 3.90
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Clearance of apoptotic cells: implications in health and disease. J Cell Biol (2010) 3.55
The inflammasomes: mechanisms of activation and function. Curr Opin Immunol (2010) 3.41
B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature (2010) 3.24
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol (2010) 2.99
Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol (2011) 2.94
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity (2014) 2.86
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2012) 2.71
A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J (2012) 2.45
Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity (2013) 2.45
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev (2009) 2.35
Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A (2010) 2.33
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev (2011) 2.14
RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells. Science (2015) 2.09
Immune microenvironments in solid tumors: new targets for therapy. Genes Dev (2011) 2.08
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Living in the liver: hepatic infections. Nat Rev Immunol (2012) 2.03
Ion channels in innate and adaptive immunity. Annu Rev Immunol (2015) 1.99
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
The receptor NLRP3 is a transcriptional regulator of TH2 differentiation. Nat Immunol (2015) 1.89
Inflammasomes: current understanding and open questions. Cell Mol Life Sci (2010) 1.87
Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol (2012) 1.85
Nucleotide signalling during inflammation. Nature (2014) 1.85
Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol (2012) 1.76
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immun (2013) 1.71
Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nat Cell Biol (2015) 1.63
NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8⁺ T cells. Nat Immunol (2012) 1.62
NLR functions beyond pathogen recognition. Nat Immunol (2011) 1.57
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol (2011) 1.56
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One (2014) 1.48
Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther (2013) 1.41
Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39
Inflammasomes: far beyond inflammation. Nat Immunol (2012) 1.38
Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev (2011) 1.35
Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia (2011) 1.34
The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia (2010) 1.33
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology (2014) 1.30
P2X7 receptor regulation of non-classical secretion from immune effector cells. Cell Microbiol (2012) 1.28
Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1β via caspase-8 in dendritic cells. J Immunol (2013) 1.28
Radiation-induced effects and the immune system in cancer. Front Oncol (2012) 1.27
Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res (2013) 1.27
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. Immunity (2013) 1.26
Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One (2011) 1.26
Lack of the purinergic receptor P2X(7) results in resistance to contact hypersensitivity. J Exp Med (2010) 1.25
Strange attractors: DAMPs and autophagy link tumor cell death and immunity. Cell Death Dis (2013) 1.25
Caspase-1 dependent IL-1β secretion is critical for host defense in a mouse model of Chlamydia pneumoniae lung infection. PLoS One (2011) 1.25
Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ (2013) 1.25
Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol (2010) 1.23
ATP release and purinergic signaling in NLRP3 inflammasome activation. Front Immunol (2013) 1.23
The Role of NLR-related Protein 3 Inflammasome in Host Defense and Inflammatory Diseases. Int Neurourol J (2012) 1.23
Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity. Front Immunol (2013) 1.22
Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. J Exp Med (2011) 1.22
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment. Cell (2016) 1.21
Dendritic cell metabolism. Nat Rev Immunol (2015) 1.21
Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med (2012) 1.19
Purinergic signalling and cancer. Purinergic Signal (2013) 1.18
Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis (2010) 1.18
The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res (2010) 1.18
Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol (2013) 1.17
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A (2011) 1.17
The interplay between autophagy and ROS in tumorigenesis. Front Oncol (2012) 1.17
Toll-like receptor agonists: are they good adjuvants? Cancer J (2010) 1.16
The role of chemokines and their receptors in angiogenesis. Cell Mol Life Sci (2011) 1.15
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol (2013) 1.15
Genetic and molecular basis of inflammasome-mediated disease. J Biol Chem (2011) 1.15
Sterile inflammatory responses mediated by the NLRP3 inflammasome. Eur J Immunol (2010) 1.14
Chronic inflammation in cancer development. Front Immunol (2012) 1.14
Tumour inflammasome-derived IL-1β recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma. EMBO Mol Med (2012) 1.14
Glucocorticoids sensitize the innate immune system through regulation of the NLRP3 inflammasome. J Biol Chem (2011) 1.14
Oncolytic viruses as anticancer vaccines. Front Oncol (2014) 1.13
Chemoimmunotherapy. Cancer J (2010) 1.13
Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 1.12
Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ (2013) 1.12
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov (2015) 1.12
Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39. Oncoimmunology (2012) 1.12
Dendritic cells and the control of immunity. Nature (1998) 56.54
Pathogen recognition and innate immunity. Cell (2006) 44.14
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell (2002) 20.11
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
Toll-like receptors and innate immunity. Nat Rev Immunol (2001) 16.50
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
The danger model: a renewed sense of self. Science (2002) 13.85
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (2007) 12.91
Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature (2002) 11.05
Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity (2006) 10.58
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature (2008) 9.16
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature (2008) 9.01
A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol (2002) 8.79
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 7.25
The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol (2007) 6.81
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J Biol Chem (2006) 5.92
Altered cytokine production in mice lacking P2X(7) receptors. J Biol Chem (2001) 5.74
Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu Rev Immunol (2006) 5.35
The P2X7 receptor: a key player in IL-1 processing and release. J Immunol (2006) 5.35
Nod-like proteins in immunity, inflammation and disease. Nat Immunol (2006) 5.25
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85
Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria. J Biol Chem (2007) 4.27
Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ (2006) 4.16
The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J Biol Chem (2002) 4.02
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature (2009) 3.93
Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther (2006) 3.93
The inflammasome: first line of the immune response to cell stress. Cell (2006) 3.73
Interleukin-1 beta, interleukin-18, and the interleukin-1 beta converting enzyme. Ann N Y Acad Sci (1998) 3.62
Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J Biol Chem (2001) 3.37
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci (2007) 3.01
Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res (2007) 2.62
Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ (2007) 2.58
Purinergic modulation of interleukin-1 beta release from microglial cells stimulated with bacterial endotoxin. J Exp Med (1997) 2.52
Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J Exp Med (1991) 2.00
The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol (2005) 1.89
A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem (2001) 1.77
Inflammation and cancer: a double-edged sword. Cancer Cell (2007) 1.52
Programming CD8+ T cells for effective immunotherapy. Curr Opin Immunol (2006) 1.51
Glu496 to Ala polymorphism in the P2X7 receptor impairs ATP-induced IL-1 beta release from human monocytes. J Immunol (2004) 1.40
Water induces autocrine stimulation of tumor cell killing through ATP release and P2 receptor binding. Cell Death Differ (2004) 1.06
The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr Top Microbiol Immunol (2006) 1.05
Genetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear? Curr Opin Rheumatol (2007) 0.88
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 24.43
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell (2002) 20.11
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature (2005) 17.47
Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science (2008) 16.54
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol (2007) 15.47
The hallmarks of aging. Cell (2013) 14.29
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
The pathophysiology of mitochondrial cell death. Science (2004) 13.87
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
A role for mitochondria in NLRP3 inflammasome activation. Nature (2010) 13.21
The inflammasomes: guardians of the body. Annu Rev Immunol (2009) 12.89
Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J (2007) 11.72
Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell (2003) 11.07
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med (2006) 10.48
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27
Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol (2009) 9.24
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Adaptive immunity maintains occult cancer in an equilibrium state. Nature (2007) 8.14
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
NKT cells: what's in a name? Nat Rev Immunol (2004) 7.84
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol (2007) 6.81
Immunological aspects of cancer chemotherapy. Nat Rev Immunol (2008) 6.61
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med (2015) 6.38
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol (2006) 6.13
Inflammatory caspases: linking an intracellular innate immune system to autoinflammatory diseases. Cell (2004) 6.06
Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5.99
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97
Autophagy and aging. Cell (2011) 5.96
RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol (2004) 5.74
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Cytoplasmic functions of the tumour suppressor p53. Nature (2009) 5.23
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Induction of autophagy by spermidine promotes longevity. Nat Cell Biol (2009) 5.00
Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature (2009) 5.00
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol (2004) 4.89
Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 4.75
Cell death by necrosis: towards a molecular definition. Trends Biochem Sci (2006) 4.67
IL-21 acts directly on B cells to regulate Bcl-6 expression and germinal center responses. J Exp Med (2010) 4.65
A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther (2007) 4.65
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J Immunol (2006) 4.48
The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer (2008) 4.42
Bcl-2 family members: dual regulators of apoptosis and autophagy. Autophagy (2008) 4.42
Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med (2006) 4.38
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science (2004) 4.17
NLRs join TLRs as innate sensors of pathogens. Trends Immunol (2005) 4.12
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism. J Exp Med (2010) 4.04
The anticancer immune response: indispensable for therapeutic success? J Clin Invest (2008) 4.01